@crownderm: Are you wondering whether Ritlecitinib or Baricitinib is the better JAK inhibitor for you?Both can treat alopecia areata, but they work differently. Ritlecitinib (Litfulo) targets JAK3 and TEC kinases. It is approved for people 12 years and older, is taken once daily, and often needs fewer lab tests. Unlike Baricitinib, which works on JAK1 and JAK2 and is approved for adults with severe alopecia areata and usually requires more blood tests before and during treatment. Remember, neither medication is a cure, and each has its own possible side effects. So, choose the best option depending on your age, how severe your condition is, and your medical history. Send this post to someone thinking about trying either medication. #drmariambalogun #dermatologist #alopecia #alopeciaareata #hairgrowth